Annual Revenue Comparison: Takeda Pharmaceutical Company Limited vs Travere Therapeutics, Inc.

Takeda's Revenue Soars, Travere Faces Volatility

__timestampTakeda Pharmaceutical Company LimitedTravere Therapeutics, Inc.
Wednesday, January 1, 2014177782400000028203205
Thursday, January 1, 2015180737800000099892000
Friday, January 1, 20161732051000000133591000
Sunday, January 1, 20171770531000000154937000
Monday, January 1, 20182097224000000164246000
Tuesday, January 1, 20193291188000000175338000
Wednesday, January 1, 20203197812000000198321000
Friday, January 1, 20213569006000000227490000
Saturday, January 1, 20224027478000000212018000
Sunday, January 1, 20234263762000000145238000
Monday, January 1, 20244263762000000
Loading chart...

Data in motion

A Tale of Two Companies: Takeda vs. Travere

In the ever-evolving pharmaceutical industry, revenue growth is a key indicator of a company's success. Takeda Pharmaceutical Company Limited, a global leader, has shown a remarkable upward trajectory in its annual revenue from 2014 to 2023. Starting at approximately 1.8 trillion in 2014, Takeda's revenue surged by over 140% to reach an impressive 4.3 trillion by 2023. This growth reflects Takeda's strategic acquisitions and expansion into new markets.

In contrast, Travere Therapeutics, Inc., a smaller player, has experienced more modest growth. From 2014 to 2022, Travere's revenue increased from around 28 million to 227 million, marking an eightfold increase. However, 2023 saw a decline to 145 million, highlighting the volatility smaller companies face in this competitive sector.

This comparison underscores the diverse challenges and opportunities within the pharmaceutical industry, where size and strategy significantly impact financial outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025